General Biologicals (GBC) held its shareholders’ meeting on the 17th, saying the group is moving from restructuring into scaled, international growth. The precision medicine company is betting on clear long-term demand in global precision medicine, smart healthcare, and regenerative medicine as it expands its CLIA/AIO systems, circulating tumor cell (CTC) testing technology, Oh care brand, and overseas footprint.